COVID-19 Impact on Inovio Pharmaceuticals Inc. Report 2020

This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Single User License: US $ 495

Purchase this Report @

Scope of this Report-
– The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
– Inovio’s pipeline is most active in early-stage drug development
– INO-4800 is Inovio’s COVID-19 vaccine
– Funding from different sources for INO-4800

Reasons to Buy this Report-
– An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.

Table of Contents in this Report-
1 Executive Summary
2 Company Overview
2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Forecast Overview
3 Regional Analysis
3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials
4 Reaction to COVID-19
4.1 INO-4800
4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals
4.3 Global Analyst Consensus Sales Forecast
4.4 Upcoming Events
4.5 Recent Deal Activity
5 Key Findings
6 Appendix
6.1 Methodology

Share This Post